LLY

723.52

-0.17%↓

JNJ

180.91

+0.71%↑

ABBV

220.83

+0.05%↑

UNH

343.05

-0.32%↓

NVO

55.34

-0.47%↓

LLY

723.52

-0.17%↓

JNJ

180.91

+0.71%↑

ABBV

220.83

+0.05%↑

UNH

343.05

-0.32%↓

NVO

55.34

-0.47%↓

LLY

723.52

-0.17%↓

JNJ

180.91

+0.71%↑

ABBV

220.83

+0.05%↑

UNH

343.05

-0.32%↓

NVO

55.34

-0.47%↓

LLY

723.52

-0.17%↓

JNJ

180.91

+0.71%↑

ABBV

220.83

+0.05%↑

UNH

343.05

-0.32%↓

NVO

55.34

-0.47%↓

LLY

723.52

-0.17%↓

JNJ

180.91

+0.71%↑

ABBV

220.83

+0.05%↑

UNH

343.05

-0.32%↓

NVO

55.34

-0.47%↓

Kodu・Aktsiate loetelu・Arbutus Biopharma Corp

Arbutus Biopharma Corp

Avatud

4.45 1.14

Osta Müü

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

4.36

Max

4.46

Põhinäitajad
By Trading Economics
Sissetulek	27M 2.5M
Müük	9M 11M
Kasumimarginaal	23.494
Töötajad	44
EBITDA	27M 2.6M

Turustatistika
By TradingEconomics
Turukapital	210M 849M
Eelmine avamishind	3.31
Eelmine sulgemishind	4.45

Tehniline skoor

By Trading Central

Kindlus

Weak Bearish Evidence

3.255 / 3.365 Toetus ja vastupanu

Arbutus Biopharma Corp Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

26. sept 2025, 18:25 UTC

Suurimad hinnamuutused turgudel

Mirion Technologies Stock Rises on Expanded Notes, Shares Offerings

28. sept 2025, 23:48 UTC

Market Talk

Nikkei May Rise After Friday's Stock Gains on Wall Street -- Market Talk

28. sept 2025, 23:48 UTC

Market Talk

Global Equities Roundup: Market Talk

28. sept 2025, 23:45 UTC

Market Talk

Gold Rises Amid Fed Rate-Cut Hopes -- Market Talk

28. sept 2025, 23:34 UTC

Market Talk

Oil Falls on Likely Technical Correction -- Market Talk

27. sept 2025, 04:15 UTC

Market Talk

Global Commodities Roundup: Market Talk

26. sept 2025, 21:56 UTC

Omandamised, ülevõtmised, äriostud

Staar Surgical, Insight Enterprises, and More Stocks See Action From Activist Investors -- Barrons.com

26. sept 2025, 20:54 UTC

Tulu

U.S. TikTok for $14 Billion? Making Sense of the Bargain-Basement Price. -- Barrons.com

26. sept 2025, 20:50 UTC

Market Talk

Tech, Media & Telecom Roundup: Market Talk

26. sept 2025, 20:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

26. sept 2025, 20:27 UTC

Omandamised, ülevõtmised, äriostud

Electronic Arts Stock Pops on Report Videogame Maker Is Close to Going Private -- Barrons.com

26. sept 2025, 20:15 UTC

Market Talk

Global Commodities Roundup: Market Talk

26. sept 2025, 19:54 UTC

Market Talk

Canada's Can't-Build Reputation Is Somewhat Earned -- Market Talk

26. sept 2025, 19:53 UTC

Omandamised, ülevõtmised, äriostud

Electronic Arts Stock Pops on Report Videogame Maker Is Close to Going Private -- Barrons.com

26. sept 2025, 19:40 UTC

Tulu

The U.S. TikTok Is Apparently Fetching a Bargain-Basement Price. A Few Reasons Why. -- Barrons.com

26. sept 2025, 19:24 UTC

Market Talk

U.S. Natural Gas Futures Mixed As October Expires -- Market Talk

26. sept 2025, 19:17 UTC

Market Talk

Oil Posts Weekly Gains on Russia-Ukraine Tensions -- Market Talk

26. sept 2025, 19:15 UTC

Market Talk

AI Deployment Beginning to Weigh on Job Creation, Former Central Banker Says -- Market Talk

26. sept 2025, 19:03 UTC

Market Talk

Global Equities Roundup: Market Talk

26. sept 2025, 19:03 UTC

Market Talk

Gold Fuels Stellar Performance in Toronto Stock Market -- Market Talk

26. sept 2025, 18:50 UTC

Market Talk

Tulu

Costco's Executive Membership Gains Seen as Offsetting Slower Renewal Rates -- Market Talk

26. sept 2025, 18:36 UTC

Market Talk

Silver Closes Out Week With Strong Surge -- Market Talk

26. sept 2025, 18:02 UTC

Omandamised, ülevõtmised, äriostud

ING: Continue Working Towards Completing Transaction, Exit From Russian Market >ING

26. sept 2025, 18:02 UTC

Omandamised, ülevõtmised, äriostud

ING: Global Development Hasn't Received All Necessary Approvals >ING

26. sept 2025, 18:02 UTC

Omandamised, ülevõtmised, äriostud

ING: No Realistic Prospect of Completing Sale of ING Bank (Eurasia) to Global Development in 3Q

26. sept 2025, 17:54 UTC

Market Talk

U.S. Oil Rig Count Rises For Fifth Straight Week -- Market Talk

26. sept 2025, 16:56 UTC

Market Talk

Tulu

Costco Increasingly Challenged to Meet Lofty Expectations -- Market Talk

26. sept 2025, 16:41 UTC

Market Talk

Tulu

Costco's Valuation Seen as Too High Amid Slow Down -- Market Talk

26. sept 2025, 16:26 UTC

Tulu

Correction to Sherwin-Williams Extends Losses. What's Ailing the Paint Maker. -- Barrons.com

26. sept 2025, 16:20 UTC

Market Talk

Basic Materials Roundup: Market Talk

Võrdlus sarnastega

Hinnamuutus

Arbutus Biopharma Corp Prognoos

Hinnangu Konsensus

By TipRanks

0 ratings

Osta

Hoia

Müü

Põhineb 0 analüütiku instrumendi Arbutus Biopharma Corp aktsia reitingul - viimase 3 kuu andmed.

Tehniline skoor

By Trading Central

3.255 / 3.365Toetus ja vastupanu

Recent bearish events outweigh bullish events.

Recent bullish events outweigh bearish events.

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

Ettevõttest Arbutus Biopharma Corp

Arbutus Biopharma Corporation, a biopharmaceutical company, develops novel therapeutics for chronic Hepatitis B virus (HBV) infection in the United States. Its HBV product pipeline consists of imdusiran (AB-729), a proprietary subcutaneously-delivered RNAi therapeutic product candidate that suppresses all HBV antigens, including HBsAg expression. The company's research and development programs include AB-101, an oral PD-L1 inhibitor to reawaken patients' HBV-specific immune system; and small molecule antiviral medicines to treat coronaviruses, including COVID-19. It has licensing agreements with Gritstone Oncology, Inc; Alnylam Pharmaceuticals, Inc.; Qilu Pharmaceuticals Co, Ltd; Assembly Biosciences, Inc.; Acuitas Therapeutics, Inc.; and Antios Therapeutics, Inc. Arbutus Biopharma Corporation also has a clinical collaboration agreement with Barinthus Biotherapeutics plc to evaluate VTP-300. The company was formerly known as Tekmira Pharmaceuticals Corporation and changed its name to Arbutus Biopharma Corporation in July 2015. Arbutus Biopharma Corporation is headquartered in Warminster, Pennsylvania.